JP2019108277A5 - - Google Patents

Download PDF

Info

Publication number
JP2019108277A5
JP2019108277A5 JP2017240652A JP2017240652A JP2019108277A5 JP 2019108277 A5 JP2019108277 A5 JP 2019108277A5 JP 2017240652 A JP2017240652 A JP 2017240652A JP 2017240652 A JP2017240652 A JP 2017240652A JP 2019108277 A5 JP2019108277 A5 JP 2019108277A5
Authority
JP
Japan
Prior art keywords
ras
raf
mek
cell growth
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017240652A
Other languages
English (en)
Japanese (ja)
Other versions
JP6952594B2 (ja
JP2019108277A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2017240652A priority Critical patent/JP6952594B2/ja
Priority claimed from JP2017240652A external-priority patent/JP6952594B2/ja
Priority to PCT/JP2018/045627 priority patent/WO2019117188A1/ja
Priority to US16/772,578 priority patent/US20200370050A1/en
Publication of JP2019108277A publication Critical patent/JP2019108277A/ja
Publication of JP2019108277A5 publication Critical patent/JP2019108277A5/ja
Priority to JP2021122479A priority patent/JP2021183618A/ja
Application granted granted Critical
Publication of JP6952594B2 publication Critical patent/JP6952594B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017240652A 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 Expired - Fee Related JP6952594B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2017240652A JP6952594B2 (ja) 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
PCT/JP2018/045627 WO2019117188A1 (ja) 2017-12-15 2018-12-12 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
US16/772,578 US20200370050A1 (en) 2017-12-15 2018-12-12 Cell proliferation inhibitor and cancer treatment or prevention pharmaceutical composition including cell proliferation inhibitor
JP2021122479A JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017240652A JP6952594B2 (ja) 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021122479A Division JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Publications (3)

Publication Number Publication Date
JP2019108277A JP2019108277A (ja) 2019-07-04
JP2019108277A5 true JP2019108277A5 (https=) 2020-09-24
JP6952594B2 JP6952594B2 (ja) 2021-10-20

Family

ID=66820498

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017240652A Expired - Fee Related JP6952594B2 (ja) 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
JP2021122479A Pending JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021122479A Pending JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Country Status (3)

Country Link
US (1) US20200370050A1 (https=)
JP (2) JP6952594B2 (https=)
WO (1) WO2019117188A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
US20240141353A1 (en) * 2022-10-26 2024-05-02 David M. Evans Sirnas against kras and raf1
WO2025104494A2 (en) * 2023-11-13 2025-05-22 Versameb Ag Compositions and methods for modulating protein interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582995A (en) * 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
WO2009143372A2 (en) * 2008-05-21 2009-11-26 Intradigm Corporation Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
RU2639459C2 (ru) * 2011-06-21 2017-12-21 Нитто Денко Корпорейшн Апоптоз-индуцирующее средство
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
JP6864990B2 (ja) * 2015-04-16 2021-04-28 日東電工株式会社 Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Similar Documents

Publication Publication Date Title
Saini et al. Inducible nitric oxide synthase: An asset to neutrophils
Shen et al. Tailoring chemoimmunostimulant bioscaffolds for inhibiting tumor growth and metastasis after incomplete microwave ablation
Shen et al. Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities
JP2018521983A5 (https=)
AU2023285759B2 (en) DPEP-1 binding compositions and methods of use
JP2015518818A5 (https=)
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2017538680A5 (https=)
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
JP2015510393A5 (https=)
JP2019108277A5 (https=)
JP2019525753A5 (https=)
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
HK1249433A1 (zh) 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
JP2006501165A5 (https=)
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
Ebner et al. Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference
RU2018142174A (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
Copland et al. Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity
Rambach et al. Secretion of a fungal protease represents a complement evasion mechanism in cerebral aspergillosis
Maria Goncalves et al. The role of the complex USP1/WDR48 in differentiation and proliferation processes in cancer stem cells
WO2020060779A3 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle